These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35091456)

  • 21. Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan.
    Otsuka M; Sugihara S; Mori S; Hamada K; Sasaki Y; Yoshikawa S; Kiyohara Y
    J Dermatol; 2020 Apr; 47(4):356-362. PubMed ID: 31984569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory markers in autoimmunity induced by checkpoint inhibitors.
    Husain B; Kirchberger MC; Erdmann M; Schüpferling S; Abolhassani AR; Fröhlich W; Berking C; Heinzerling L
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1623-1630. PubMed ID: 33837821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
    Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors.
    Byrne MM; Lucas M; Pai L; Breeze J; Parsons SK
    Eur J Haematol; 2021 Dec; 107(6):650-657. PubMed ID: 34453348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
    Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
    Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disordered Antigens and Epitope Overlap Between Anti-Citrullinated Protein Antibodies and Rheumatoid Factor in Rheumatoid Arthritis.
    Zheng Z; Mergaert AM; Fahmy LM; Bawadekar M; Holmes CL; Ong IM; Bridges AJ; Newton MA; Shelef MA
    Arthritis Rheumatol; 2020 Feb; 72(2):262-272. PubMed ID: 31397047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study.
    Kobayashi T; Iwama S; Yasuda Y; Okada N; Okuji T; Ito M; Onoue T; Goto M; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Suga H; Banno R; Yokota K; Hase T; Morise M; Hashimoto N; Ando M; Fujimoto Y; Hibi H; Sone M; Ando Y; Akiyama M; Hasegawa Y; Arima H
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32606047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
    Atzeni F; Sarzi-Puttini P; Dell' Acqua D; de Portu S; Cecchini G; Cruini C; Carrabba M; Meroni PL
    Arthritis Res Ther; 2006; 8(1):R3. PubMed ID: 16356192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors: A Systematic Literature Review.
    Ghosh N; Chan KK; Jivanelli B; Bass AR
    J Clin Rheumatol; 2022 Mar; 28(2):e498-e505. PubMed ID: 34371516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.
    von Itzstein MS; Yang Y; Wang Y; Hsiehchen D; Sheffield TY; Fattah F; Popat V; Ahmed M; Homsi J; Dowell JE; Rashdan S; Lohrey J; Hammers HJ; Hughes RS; Wang T; Xie Y; Gerber DE
    Front Immunol; 2024; 15():1351739. PubMed ID: 38690281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia.
    Ten Brinck RM; van Steenbergen HW; van Delft MAM; Verheul MK; Toes REM; Trouw LA; van der Helm-van Mil AHM
    Rheumatology (Oxford); 2017 Dec; 56(12):2145-2153. PubMed ID: 28968865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between immune-related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis.
    Euvrard R; Robert M; Mainbourg S; Dalle S; Lega JC
    Fundam Clin Pharmacol; 2024 Apr; 38(2):369-379. PubMed ID: 38012082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.
    Nell VP; Machold KP; Stamm TA; Eberl G; Heinzl H; Uffmann M; Smolen JS; Steiner G
    Ann Rheum Dis; 2005 Dec; 64(12):1731-6. PubMed ID: 15878904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
    Hribernik N; Huff DT; Studen A; Zevnik K; Klaneček Ž; Emamekhoo H; Škalic K; Jeraj R; Reberšek M
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1857-1869. PubMed ID: 34958422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
    Us D; Gülmez D; Hasçelik G
    Mikrobiyol Bul; 2003; 37(2-3):163-70. PubMed ID: 14593899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expansion of Alternative Autoantibodies Does Not Follow the Evolution of Anti-Citrullinated Protein Antibodies in Preclinical Rheumatoid Arthritis: An Analysis in At-Risk First Degree Relatives.
    Anaparti V; Smolik I; Meng X; O'Neil L; Jantz MA; Fritzler MJ; El-Gabalawy H
    Arthritis Rheumatol; 2021 May; 73(5):740-749. PubMed ID: 33538122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies.
    Les I; Martínez M; Narro A; Pérez I; Sánchez C; Puntí L; Anaut P; Eguiluz S; Herrera A; Domínguez S
    Ann Med; 2021 Dec; 53(1):762-769. PubMed ID: 34060971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for ANA positivity in healthy persons.
    Li QZ; Karp DR; Quan J; Branch VK; Zhou J; Lian Y; Chong BF; Wakeland EK; Olsen NJ
    Arthritis Res Ther; 2011 Mar; 13(2):R38. PubMed ID: 21366908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.
    Petro AD; Dougherty J; England BR; Sayles H; Duryee MJ; Hunter CD; Kremer JM; Pappas DA; Robinson WH; Curtis JR; Thiele GM; Mikuls TR
    Int Immunopharmacol; 2021 Feb; 91():107260. PubMed ID: 33360371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.